Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
14.1 USD | -2.32% | +2.29% | +34.72% |
Financials (USD)
Sales 2024 * | 15.86B | Sales 2025 * | 16.28B | Capitalization | 16.18B |
---|---|---|---|---|---|
Net income 2024 * | 420M | Net income 2025 * | 743M | EV / Sales 2024 * | 1.94 x |
Net Debt 2024 * | 14.62B | Net Debt 2025 * | 12.12B | EV / Sales 2025 * | 1.74 x |
P/E ratio 2024 * |
19.9
x | P/E ratio 2025 * |
15.4
x | Employees | 35,737 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.57% |
Latest transcript on Teva Pharmaceutical Industries Limited
1 day | +2.05% | ||
1 week | +7.05% | ||
Current month | +9.73% | ||
1 month | +8.50% | ||
3 months | +37.04% | ||
6 months | +44.16% | ||
Current year | +38.22% |
Managers | Title | Age | Since |
---|---|---|---|
Richard Francis
CEO | Chief Executive Officer | 55 | 22-12-31 |
Eli Kalif
DFI | Director of Finance/CFO | 51 | 19-12-21 |
Eric Hughes
CTO | Chief Tech/Sci/R&D Officer | - | 22-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Gerald Lieberman
BRD | Director/Board Member | 77 | 15-08-31 |
Janet Vergis
BRD | Director/Board Member | 60 | 20-06-08 |
Sol Barer
CHM | Chairman | 76 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
6.38% | 13 M€ | -.--% | ||
0.27% | 18 M€ | +7.01% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 14.06 | -2.53% | 6 600 389 |
24-03-27 | 14.43 | +2.05% | 12,252,173 |
24-03-26 | 14.14 | +0.57% | 7,542,987 |
24-03-25 | 14.06 | +1.22% | 8,037,381 |
24-03-22 | 13.89 | +1.02% | 9,282,574 |
Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.22% | 16.18B | |
+33.50% | 701B | |
+26.24% | 571B | |
+0.78% | 381B | |
+20.85% | 334B | |
+16.38% | 319B | |
+2.43% | 210B | |
+1.17% | 210B | |
-6.56% | 201B | |
-3.51% | 157B |